Moderna, Inc. $MRNA Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 54.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 47,000 shares of the company’s stock after selling 56,433 shares during the period. Privium Fund Management B.V.’s holdings in Moderna were worth $1,214,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of MRNA. Rothschild Investment LLC grew its position in shares of Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after acquiring an additional 446 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of Moderna during the 2nd quarter worth approximately $26,000. Whittier Trust Co. purchased a new position in Moderna in the second quarter worth $28,000. MUFG Securities EMEA plc acquired a new stake in shares of Moderna in the second quarter valued at about $28,000. Finally, Cromwell Holdings LLC acquired a new stake in shares of Moderna during the 2nd quarter valued at approximately $33,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the sale, the director owned 3,924 shares in the company, valued at $115,679.52. The trade was a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MRNA. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a report on Monday, January 5th. Citigroup reaffirmed a “neutral” rating on shares of Moderna in a research report on Monday, January 19th. Morgan Stanley lowered their target price on shares of Moderna from $30.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Barclays started coverage on Moderna in a research note on Wednesday. They set an “equal weight” rating and a $25.00 price target for the company. Finally, UBS Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $40.00 to $34.00 in a research report on Tuesday, January 6th. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $28.77.

Moderna Trading Down 6.0%

MRNA stock opened at $44.07 on Friday. The company has a market capitalization of $17.22 billion, a P/E ratio of -5.46 and a beta of 1.17. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $55.20. The firm has a 50 day simple moving average of $33.96 and a 200-day simple moving average of $29.25.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The company’s revenue for the quarter was down 45.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.03 EPS. On average, research analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna announced a global commercialization collaboration with Recordati for its investigational propionic acidemia therapy mRNA‑3927, under which Moderna keeps development control and can receive up to $160M in upfront/near‑term milestones plus royalties — a near‑term cash and de‑risking event for a rare‑disease program. RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA
• Positive Sentiment: Moderna named Dr. David Berman as Chief Development Officer effective March 2, 2026 — a senior hire that could bolster investor confidence in clinical execution and pipeline progression. Dr. David Berman to Join Moderna as Chief Development Officer
• Neutral Sentiment: Barclays has initiated coverage of Moderna, which can influence flows depending on the firm’s rating and target but is not an immediate operational development. Barclays Initiates Coverage on Moderna
• Neutral Sentiment: Public commentary (e.g., Jim Cramer) remains mixed — high-profile media comments can sway retail interest but don’t change fundamentals. Jim Cramer on Moderna: “We Have to Wait and See”
• Negative Sentiment: Chief Medical Officer Jacqueline Miller, a leader on Spikevax and key development executive, will step down effective March 2 — leadership turnover in clinical oversight raises near‑term execution uncertainty. Moderna CMO Jacqueline Miller to step down
• Negative Sentiment: Reports that Moderna is rethinking late‑stage vaccine funding and investor risk allocation have raised concerns about how the company will finance and prioritize its pipeline, compounding worries from prior quarters of falling COVID vaccine revenue and negative EPS. Moderna Rethinks Late Stage Vaccine Funding And Investor Risk Balance

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.